Teva Pharmaceutical Industries (NYSE:TEVA) Downgraded by StockNews.com to Hold

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) was downgraded by research analysts at StockNews.com from a "buy" rating to a "hold" rating in a research note issued on Monday.

TEVA has been the topic of a number of other research reports. Barclays reduced their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Thursday, January 30th. Bank of America decreased their price target on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a research note on Thursday, March 6th. Piper Sandler increased their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a research report on Friday, January 17th. Finally, UBS Group reduced their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a report on Thursday, January 30th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $23.43.

Teva Pharmaceutical Industries Price Performance

Shares of Teva Pharmaceutical Industries stock traded up $0.18 on Monday, hitting $13.61. 8,836,138 shares of the company traded hands, compared to its average volume of 9,899,841. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The business has a 50-day simple moving average of $15.51 and a 200 day simple moving average of $17.70. Teva Pharmaceutical Industries has a 52 week low of $12.47 and a 52 week high of $22.80. The stock has a market capitalization of $15.43 billion, a P/E ratio of -9.38, a price-to-earnings-growth ratio of 1.44 and a beta of 0.72.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Research analysts expect that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current fiscal year.

Institutional Trading of Teva Pharmaceutical Industries

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TEVA. Oarsman Capital Inc. bought a new position in shares of Teva Pharmaceutical Industries during the fourth quarter valued at approximately $29,000. Marshall & Sterling Wealth Advisors Inc. bought a new position in Teva Pharmaceutical Industries in the fourth quarter worth approximately $44,000. Wilmington Savings Fund Society FSB purchased a new position in Teva Pharmaceutical Industries during the 3rd quarter worth $50,000. Compagnie Lombard Odier SCmA purchased a new stake in shares of Teva Pharmaceutical Industries in the 1st quarter worth $54,000. Finally, Ameliora Wealth Management Ltd. bought a new position in shares of Teva Pharmaceutical Industries during the 4th quarter worth $66,000. 54.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.